Filing Details

Accession Number:
0001325812-13-000008
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-12-04 17:01:58
Reporting Period:
2013-12-02
Filing Date:
2013-12-04
Accepted Time:
2013-12-04 17:01:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178670 Alnylam Pharmaceuticals Inc. ALNY Pharmaceutical Preparations (2834) 770602661
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1514291 Michael Mason 300 3Rd Street
Cambridge MA 02142
Vp, Finance And Treasurer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-12-02 3,750 $7.10 11,597 No 4 M Direct
Common Stock Disposition 2013-12-02 1,905 $61.55 9,692 No 4 S Direct
Common Stock Disposition 2013-12-02 1,845 $62.12 7,847 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2013-12-02 3,750 $0.00 3,750 $7.10
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,500 2021-11-30 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,906 Indirect by Managed Account
Footnotes
  1. The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2012.
  2. Sale prices ranged from $60.89 to $61.85.
  3. Sale prices ranged from $61.90 to $62.49.
  4. The reporting person owns 1,906 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
  5. The stock option vests as to 25% of the shares on the 1st anniversary of the stock option grant date and as to an additional 6.25% of the shares each successive three month period thereafter.